key: cord-1017911-yyt2zos9
authors: Swed, Sarya; Baroudi, Ihsan; Ezzdean, Weaam; Sawa, Bisher; Bohsas, Haidara; Patwary, Muhammad Mainuddin
title: COVID-19 vaccine hesitancy among people in Syria: An incipient crisis
date: 2022-02-01
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2022.103324
sha: 67d5549fdef1432b1f20142c7312ae7e911004fb
doc_id: 1017911
cord_uid: yyt2zos9

nan

To the editor , Covid-19 is a global health threat as it spreads widely and rapidly. This pandemic was first detected at the end of December in Wuhan city of China. [1] The first case in Syria was reported on 22 March 2020. [2] Syria's Healthcare Capacity to respond to a COVID-19 Outbreak was rapid but not sufficient as the Syrian war made a bad impact on Syria's Healthcare to face another crisis.

The Syrian Ministry of Health Committed the World Health Organization (WHO) Covid-19 management guidelines but a necessity to reduce prevalence and death rate suppose the need of a safe and effective vaccine. [3] Multiple available vaccines had been developed, but the big challenge was when vaccine hesitancy appeared. [3] Syria's Healthcare faces vaccines hesitancy challenges in the different sites from Syria, especially rural areas. [3] Many causes influenced the acceptance of the vaccines including fear of side effects, doubts about vaccine efficiency, the vaccine is not important, and not the right time to be vaccinated, ongoing conflict, huge displacement, inflated economy and the fragile, fragmented health system, also lack of actual learning of threats of COVID-19 and the proven benefits of COVID-19 vaccine. [3] J o u r n a l P r e -p r o o f Vaccine hesitancy is the term used to define refusal or reluctance in the acceptance of vaccination despite the availability of vaccination services. The modern endorsement of vaccine hesitancy is a well-known phenomenon, with older roots that have accompanied vaccination since its scientific inception. [3] Regarding Syria with COVID-19 vaccine, many obstacles arise toward vaccination, which include Vaccine hesitancy, but also the shortage of vaccine doses offered to population in need and distribution of vaccine which limited in some governments and affected by the poor economic situation is Syria. [3] According to the WHO Syria Situation Report for June, 2021, Syria has received first batch of COVID-19 vaccines (256,800 doses of AstraZeneca SII COVIDSHILD) on 21 April 2021. 203 000 doses were allocated for Syrian governorates, including northeast Syria and 53 800 were allocated through Gaziantep to target populations in northwest Syria. In the first phase, the vaccines were allocated for frontline health workers as a priority group. [3] The Ministry of Health started vaccination with AstraZeneca on 17 May 2021. The first governorate to start the vaccination was Aleppo followed by other governorates.

The roll-out of the vaccination campaign began on 20 April (covering 13 governorates). The vaccine distrubated in Taiz, Marib, Aden, Shabwa and Hadramawt. [5] According to the Syria Covid-19 National Vaccination Plan, the priority groups during the first phase are healthcare workers, people age 55 and over, people with comorbidities, and internally displaced people and refugees. However, According to WHO only 46,397 individuals in Government-controlled areas received their first dose of vaccination by the date of 2 June. While many people in Syria began to report vaccine hesitancy. [2] J o u r n a l P r e -p r o o f Hesitancy was mainly reported in the rural areas considering these areas as communities suffering from food shortages, low immunity, and lack of proper education, and underprivileged healthcare settings that will make such communities a suitable milieu for misleading information and conspiracy beliefs. [4] Thus, reducing the willingness to be vaccinated and increasing the rates of infection spread, which puts additional burdens on the already-weakened healthcare systems. [4] On the other hand, the overwhelmed healthcare units will be less able to manage patients and monitor new cases, which in turn, will negatively affect the economy and population's trust in their healthcare systems and by that, activating the cycle again. [3] . However, logistical problems to vaccination also has an important effect of general population of ruler areas, Where purchasing power, electricity, internet access, and fuel are scarce, logistics can prohibit vaccines from reaching individuals willing to get vaccinated. [3] According to WHO the northeast of Syria and its ruler were mainly affected by such refusal and difficulty of vaccination due to several challenges including: [4] Reaching northeast Syria (especially areas not under Government control), Insufficient funds to maintain operational costs as Syria is not supported by the World Bank (COVAX does not fund operational cost), Misinformation, vaccine hesitancy and refusal of vaccination (reach beyond traditional age groups) and Clarity on the future vaccine allocations and types of vaccine that would be shipped to Syria. [2] This area is considered the most affected area as it has the lowest rate of vaccinated population. also the special considerations that must be taken for such area and it's ruler with more than 13 ruler area (Fig 1) in both AL Hassakeh governorate And Deir-Ezzor J o u r n a l P r e -p r o o f Governorate, where ruler areas is considered High risk conflict area that has low security profile which is more difficult to be reached by vaccination campaigns .

While In North West Syria, Some hesitancy among the health staff were shown due to the negative effect of rumors in the social media, there is gradual increase in the numbers of vaccinated beneficiaries. [2] Some difficulties were faced in coordination with non-health NGOs.

United Nations resolution renewal, Unclear future of vaccine shipments (dates and quantities), Funding availability. [2] As more than 46 ruler area in north west Syria [ Figure 1 ] would be considered the highest rate of ruler areas in Syria leading to more and higher rate of hesitancy in these areas which are affected by other factors: (i.e. higher poverty rate, lack of resources, underprivileged healthcare settings, misleading information, transportation difficulty). [6] .

Depending on the last WHO reports the rate of Covid-19 confirmed cases in Syria is higher than rates in other Arabic low-income countries such as Sudan , Somali ,Yemen ….etc.[7-10][ Table 1 ].

Other factors, which play role in hesitancy among ruler community, would be reconstructed areas, which are still under the effect of recently ended war, which is mostly observed in Aleppo and Damascus ruler areas that may show difficulty in reporting any need of health care and vaccination.

Based on the previously mentioned obstacles, multiple measurements should be applied to reduce the refusal and hesitancy of COVID-19 vaccination .

More detailed information should be provided about the benefits of the vaccine to raise the awareness of the importance of vaccine to fight the pandemic and reduce the multiple factor effect of living on ruler areas in COVID-19 vaccine hesitancy , wider approaching of vaccine campaigns, more funding aid to support such campaigns.

In this country , WHO and global organizations leaders should utilize a variety of "standard policy" models and leadership strategies, with the intention of getting accelerated situation monitoring, viral avoidance and control, and appropriate and adequate assignment of funds to areas of greatest need, as well as providing quite enough vaccination as possible to avoid further health issues [11] [12] [13] .

J o u r n a l P r e -p r o o f 

et alOrigin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19)

Coronavirus 2019 and health systems affected by protracted conflict: The Syria

Factors associated with the intention of Syrian adult population to accept COVID19 vaccination: a cross-sectional study

Update on COVID-19 vaccination in Syria

Factors associated with the intention of Syrian adult population to accept COVID19 vaccination: a cross-sectional study

COVID-19 SITUATION ANALYSIS CRISIS TYPE: EPIDEMIC Syria

repot covid-19 in Sudan

repot covid-19 in Somali

The socio-economic implications of the coronavirus pandemic (COVID-19): A review

World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

Health policy and leadership models during the COVID-19 pandemic: A review

J o u r n a l P r e -p r o o f

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.All authors declare no conflict of interest.Please state any sources of funding for your research All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement. Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.All authors have participated in writing and reviewing the manuscript.

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish Sarya Swed J o u r n a l P r e -p r o o f